IDEXX Laboratories, Inc.
560.38USD
-6.3800 (-1.13%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on IDXX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $3.72▼ | $3.78 | 3 | 7 |
| Next quarter | $3.36▼ | $3.45 | 1 | 8 |
| Current year | $14.84▲ | $14.66 | 11 | 0 |
| Next year | $16.74▲ | $16.52 | 11 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $3.93 | $4.27 | +0.34 (+8.5%) |
| 2026-03-31 | $3.41 | $3.47 | +0.06 (+1.7%) |
| 2025-12-31 | $2.94 | $3.08 | +0.14 (+4.8%) |
| 2025-09-30 | $3.15 | $3.4 | +0.25 (+8.1%) |
132 ratings from 20 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $775 $750 | Oct 16, 2026 |
| Keybanc | Initiated | Sector Weight | — | Oct 12, 2026 |
| Barclays | Maintained | Overweight | $800 $710 | Aug 11, 2026 |
| UBS | Maintained | Neutral | $620 $670 | Aug 5, 2026 |
| Citigroup | Maintained | Neutral | $650 $670 | Aug 5, 2026 |
| UBS | Maintained | Neutral | $640 $620 | Jul 27, 2026 |
| UBS | Maintained | Neutral | $730 $640 | Apr 28, 2026 |
| Citigroup | Initiated | Neutral | $650 | Apr 15, 2026 |
| Stifel | Maintained | Buy | $775 $675 | Mar 31, 2026 |
| Piper Sandler | Maintained | Neutral | $775 $750 | Feb 9, 2026 |
| Barclays | Maintained | Overweight | $850 $800 | Feb 5, 2026 |
| UBS | Maintained | Neutral | $750 $730 | Feb 3, 2026 |
| BTIG | Maintained | Buy | $830 $800 | Feb 3, 2026 |
| Barclays | Initiated | Overweight | $850 | Dec 9, 2025 |
| Morgan Stanley | Maintained | Overweight | $765 $805 | Nov 4, 2025 |
| UBS | Maintained | Neutral | $710 $750 | Nov 4, 2025 |
| JP Morgan | Maintained | Overweight | $675 $775 | Nov 4, 2025 |
| BTIG | Maintained | Buy | $785 $830 | Nov 4, 2025 |
| Stifel | Upgraded from Hold | Buy | $640 $700 | Oct 31, 2025 |
| UBS | Initiated | Neutral | $720 | Oct 1, 2025 |
| Morgan Stanley | Maintained | Overweight | $722 $765 | Aug 15, 2025 |
| Piper Sandler | Maintained | Neutral | $510 $700 | Aug 11, 2025 |
| JP Morgan | Maintained | Overweight | $550 $675 | Aug 4, 2025 |
| Morgan Stanley | Maintained | Overweight | $626 $722 | Aug 4, 2025 |
| Morgan Stanley | Maintained | Overweight | $548 $628 | Jul 29, 2025 |
90 filings from 20 insiders · 11 buy / 1 sell over 6m
Officers and directors of IDXX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kingsley Lawrence DDirector | ExerciseNon-Qualified Stock Option (right-to-buy) | 2.2k | — | — | Sep 4, 2026 |
| Kingsley Lawrence DDirector | Sell | 2.2k | $532.08 | $1.17M | Sep 4, 2026 |
| Kingsley Lawrence DDirector | Exercise | 2.2k | $114.17 | $252k | Sep 4, 2026 |
| EMERSON ANDREWChief Financial Officer | Exercise | 265 | $178.26 | $47k | Aug 20, 2026 |
| HOOLEY JOSEPH L.Director | Grant | 49 | $558.80 | $27k | Jul 30, 2026 |
| FENNELL GEORGEOfficer | Other | 639 | — | — | Jun 1, 2026 |
| VANDEBROEK SOPHIE VDirector | Other | 257 | — | — | May 7, 2026 |
| KINGSLEY LAWRENCE DDirector | Other | 339 | — | — | May 7, 2026 |
| HOOLEY JOSEPH L.Director | Other | 158 | — | — | May 7, 2026 |
| PEACOCK KARENDirector | Other | 101 | — | — | May 7, 2026 |
| JUNIUS DANIEL MDirector | Other | 257 | — | — | May 7, 2026 |
| SZOSTAK MARGARET ANNEDirector | Other | 257 | — | — | May 7, 2026 |
| HOOLEY JOSEPH L.Director | Grant | 43 | $560.80 | $24k | Apr 30, 2026 |
| HUNT NIMRATA KOfficer | Sell | 1.8k | $634.57 | $1.12M | Mar 3, 2026 |
| UNDERBERG SHARON EGeneral Counsel | Exercise | 197 | $505.53 | $100k | Mar 3, 2026 |
| MAZELSKY JONATHAN JAYChief Executive Officer | Exercise | 23.5k | $141.60 | $3.40M | Feb 27, 2026 |
| HUNT NIMRATA KOfficer | Sell | 2.7k | $661.54 | $1.78M | Feb 26, 2026 |
| MAZELSKY JONATHAN JAYChief Executive Officer | Sell | 23.3k | $650.67 | $15.34M | Feb 26, 2026 |
| ERICKSON MICHAEL GOfficer | Exercise | 7.8k | $141.60 | $1.46M | Feb 19, 2026 |
| ERICKSON MICHAEL GOfficer | Sell | 5.4k | $623.76 | $3.37M | Feb 17, 2026 |
No analyst notes on IDXX yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 5 | 4 | 0 | 1 | Buy2.21 |
| 1 mo ago | 4 | 4 | 4 | 0 | 1 | Buy2.23 |
| 2 mo ago | 4 | 4 | 5 | 0 | 1 | Buy2.29 |
| 3 mo ago | 4 | 5 | 5 | 0 | 1 | Buy2.27 |
Members whose judged calls on IDXX have played out most reliably.
No settled calls on IDXX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice